Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MSCI Taiwan ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while iShares MSCI Taiwan ETF trades at $103.63. Which is the better fit depends on your goals.
| ADPT | EWT | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $111.53 |
52-Week Low | $10.24 | $57.66 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EWT trades at $107.27, up 2.3% with strong bullish momentum from moving averages. The ETF has more than doubled in the past year, driven by Taiwan's semiconductor sector dominance and AI infrastructure demand. Technical indicators show neutral oscillators but overall buy signals dominate. Recent news highlights geopolitical tensions and semiconductor supply chain importance as key drivers.
Outlook remains positive given Taiwan's critical role in global tech supply chains, though stretched valuations and China-Taiwan geopolitical risks pose significant headwinds. The concentration in tech stocks like TSMC offers growth exposure but increases vulnerability to sector-specific downturns and trade disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
